Zhejiang Hangkang Pharmaceutical Co Ltd.

The main purpose of the study is to use the linezolid tablets (600 mg) certified by Pfizer Pharmaceuticals.LCC as the reference preparation and the linezolid tablets (600 mg) developed by Zhejiang Hangkang Pharmaceutical Co., Ltd. as the test preparation, and to evaluate the bioequivalence of the two preparations in the fasting and fed state through a single-center, single-dose, randomized, open, two-period, double-crossover clinical study. Secondary purpose of the study: to observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

The main purpose of the study is to use AstraZeneca AB's licensed saxagliptin tablets (specification: 5 mg, trade name: ONGLYZA) as the reference preparation and Zhejiang Hangkang Pharmaceutical Co., Ltd.'s saxagliptin tablets (specification: 5 mg) as the test preparation, and to evaluate the bioequivalence of the two preparations in the fasting and fed state through a single-center, single-dose, randomized, open, two-period, double-crossover clinical study. Secondary purpose of the study: To observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

Primary objective: To compare the differences in the extent and rate of absorption of hydroxychloroquine sulfate tablets (0.2 g) produced by Zhejiang Hangkang Pharmaceutical Co., Ltd. and hydroxychloroquine sulfate tablets (trade name: PLAQUENIL®, specification: 0.2 g) certified by Sanofi-aventis Ireland Ltd. T/A SANOFI in healthy Chinese population under fasting and postprandial administration conditions using a single-center, randomized, open, single-dose, single-period parallel trial design, and to evaluate bioequivalence. Secondary objective: To evaluate the safety of the test and reference preparations of hydroxychloroquine sulfate tablets (specification: 0.2 g) in healthy subjects.